Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer

Last updated: October 11, 2022
Sponsor: Peking Union Medical College Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Uterine Disorders

Cervical Cancer

Treatment

N/A

Clinical Study ID

NCT05531981
CC-MRD-1
  • Ages > 18
  • Female

Study Summary

In this study, a large-scale cohort of cervical cancer patients was established in multiple centers. Minimal residual disease(MRD) was assessed by ddPCR detection of HPV E7 gene ctDNA to assess tumor burden and predict the risk of disease recurrence, so as to provide new biomarkers for precise treatment of cervical cancer patients. The study continued until 36 months after the end of treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Pathological diagnosis: cervical squamous cell carcinoma, adenocarcinoma oradenosquamous carcinoma
  • FIGO stage: IA2-IVA
  • HPV typing: type 16 or 18
  • ECOG 2-0
  • The initial treatment was surgery (Cohort A) / concurrent chemoradiotherapy (Cohort B)

Exclusion

Exclusion Criteria:

  • The diagnosis of cervical cancer was made within 3 years of other malignancies
  • Pregnant or lactating women
  • Refused to sign a consent form

Study Design

Total Participants: 350
Study Start date:
September 20, 2022
Estimated Completion Date:
September 01, 2025

Study Description

The purpose of this study is to assess MRD by detecting HPV E7 gene ctDNA to assess tumor burden and predict the risk of disease recurrence. According to the treatment methods, the patients were divided into two groups :(1) initial surgical treatment group (2) initial concurrent chemoradiotherapy group.

After the patients were enrolled in the study according to the criteria, they were given standard treatment. The patients were followed up every 36 months within 2 years after treatment and every 612 months from 3 to 5 years after treatment, including general and gynecological physical examination, cervical or vaginal cytology test, HPV typing test, SCC, CA125, and imaging examination such as CT or MRI if necessary.

Peripheral blood samples were collected to detect HPV E7 ctDNA before treatment, after treatment, and at 6, 12, 18, 24, 30, and 36 months of follow-up.

The primary endpoint is Disease-free survival (DFS, time from the treatment initiation to disease progression). Secondary endpoints include HPV ctDNA state before treatment, dynamic change trend of HPV ctDNA after treatment and overall survival (OS, time from the treatment initiation to death).

Connect with a study center

  • Peking Union Medical College Hospital

    Beijing, Beijing 100730
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.